Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis

JAMA Dermatology

Volumn 150, Issue 7, 2014, Pages 724-729

  Valenzuela, Antonia ^a   Chung, Lorinda ^a   Casciola Rosen, Livia ^b   Fiorentino, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; CALCIUM; MDA 5 ANTIBODY; NXP 2 ANTIBODY; TRANSCRIPTION FACTOR; TRANSCRIPTION INTERMEDIARY FACTOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCINOSIS; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FINGERTIP ULCER; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; ULCER;

ADENOSINE TRIPHOSPHATASES; ADULT; AUTOANTIBODIES; CALCINOSIS; CROSS-SECTIONAL STUDIES; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; DNA-BINDING PROTEINS; FEMALE; FINGERS; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PHENOTYPE; RIBONUCLEOPROTEINS; SKIN ULCER; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 84904105989     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.10416     Document Type: Article

References (32)

1. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. Themucocutaneous and systemic phenotype of dermatomyositis patientswith antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25-34.
2. Clemente G, Piotto DG, Barbosa C, et al. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. Rev Bras Reumatol. 2012;52(4):549-553.
3. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012;41(1):50-58.
4. Gutierrez A Jr, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther. 2012;25(2):195-206.
5. Walsh JS, Fairley JA. Calcifying disorders of the skin. J Am Acad Dermatol. 1995;33(5, pt 1):693-710.
6. Cook CD, Rosen FS, Banker BQ. Dermatomyositis and focal scleroderma. Pediatr Clin North Am. 1963;10:979-1016.
7. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005;34(6):805-812. (Pubitemid 40732455)
8. Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB. Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol. 1984;142(2):397-400. (Pubitemid 14182104)
9. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis, part II: treatment options. J Am Acad Dermatol. 2011;65(1):15-24.
10. Chander S, Gordon P. Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol. 2012;24(2):158-164.
11. Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis. 2006;65(8):1088-1092. (Pubitemid 44133273)
12. Avouac J, Mogavero G, Guerini H, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis. 2011;70(4):630-633.
13. Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatorymyositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11:223. doi:10.1186/1471-2474-11-223.
14. Rider LG, Shah M, Mamyrova G, et al; Childhood Myositis Heterogeneity Collaborative Study Group. Themyositis autoantibody phenotypes of the juvenile idiopathic inflammatorymyopathies. Medicine (Baltimore). 2013;92(4):223-243.
15. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48(6):607-612.
16. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954-2962.
17. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatorymyopathies: possible association with malignancy. Ann Rheum Dis. 2012;71(5):710-713.
18. Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J). 2008;84(1):68-74. (Pubitemid 351287725)
19. Sanner H, Gran JT, Sjaastad I, Flatø B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford). 2009;48(12):1541-1547.
20. Gunawardena H, Wedderburn LR, Chinoy H, et al; Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807-1814.
21. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/ dermatomyositis. Arthritis Res Ther. 2012;14(2):R97.doi:10.1186/ar3822.
22. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24(6):602-608.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
24. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387-408. (Pubitemid 34840105)
25. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion bodymyositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(suppl 11):S118-S157.
26. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med. 1999;190(6): 815-826.
27. Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol. 2012;148(4):455-462.
28. Marvi U, Chung L, Fiorentino DF. Clinical presentation and evaluation of dermatomyositis. Indian J Dermatol. 2012;57(5):375-381.
29. Rider LG, Feldman BM, Perez MD, et al; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatorymyopathies, I: physician, parent, and patient global assessments. Arthritis Rheum. 1997;40(11):1976-1983. (Pubitemid 27494657)
30. Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel FA. An update on the treatment of the cutaneous manifestations of systemic sclerosis: the dermatologist's point of view. J Clin Aesthet Dermatol. 2012;5(7):33-43.
31. Zaba LC, Fiorentino DF. Skin disease in dermatomyositis. Curr Opin Rheumatol. 2012;24(6): 597-601.
32. Fiorentino DF, Chung LS, Zaba L, Lingala B, Rosen A, Casciola-Rosen L. Immune responses to NXP-2 and TIF-g are associated with distinct clinical phenotypes and prognosis for skin disease in dermatomyositis patients. Arthritis Rheum. 2012; 64(S10):S828.